Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

Not Applicable

Recruiting

• Conditions: Colorectal Cancer
• Interventions: Combination Product: CIK combined targeted therapy group; Combination Product: CIK combined with chemotherapy group; Combination Product: CIK in combination with other therapies; Combination Product: CIK combined immunotherapy group

• Registration Number: NCT05676190
• Lead Sponsor: ShiCang Yu

Brief Summary

This project plans to use CIK combined with chemotherapy, immunotherapy and targeted therapy to treat CRC patients, so as to explore the effectiveness of CIK treatment and the CRC subtypes more suitable for CIK treatment, thereby improving the survival rate and quality of life of CRC patients.

Detailed Description

Colorectal cancer (CRC) is a malignant tumor that seriously threatens human health, and according to the international agency for research on cancer (IARC) data, in 2018, the number of new cases of CRC totalled more than 1.8 million and the number of deaths totalled more than 88million, making it the third most common cancer worldwide \[1\]. In recent years, with the development of economic level in China, changes in lifestyle and dietary structure, the incidence and mortality of CRC have shown a continuous increasing trend, and it is ranked 5th in all malignant tumors. According to statistics, at present, our country has 376000 new CRC cases and 191000 deaths annually, and the whole face extremely serious challenges.

Patients with advanced CRC have a more complicated disease, and the 5-year survival rate is even less than 5%. A single therapeutic means cannot achieve the desired therapeutic effect, and often multiple therapeutic modalities are used for intervention, including surgery, radiotherapy, chemotherapy, interventional minimally invasive treatment, immunotherapy and molecular targeting, etc. Because of the potential efficacy of CIK treatment in controlling tumor growth and prolonging patient survival, but there are still few clinical studies about CIK combined with other treatment modalities, this protocol is intended to use CIK combined with chemotherapy, immune and targeted therapy in CRC patients, in order to explore the effectiveness of CIK treatment and more suitable CRC subtypes for CIK treatment, and then improve the survival rate and quality of life of CRC patients.

Study Timeline

• Status Verified: 2022-12
• Study First Submitted: 2022-12-08
• Study First Submitted QC: 2023-01-06
• Last Update Submitted: 2023-01-06
• Study Start: 2023-01-09
• Study First Posted: 2023-01-09
• Last Update Posted: 2023-01-09
• Primary Completion: 2026-12-30
• Study Completion: 2027-04-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Age range 18-70 years;

  • Patients diagnosed with colorectal cancer, TNM stage III-IV;

    • Had at least one extracranially measurable lesion by recist1.1 criteria; ④ Patients who had failed at least one or two prior lines of standard therapy or relapsed, or who were intolerant to or voluntarily abandoned one or two prior lines of standard therapy; ⑤ Expected survival ≥ 90 days;

      • The major organs function normally; ⑦ The subject voluntarily joined this study, signed the informed consent, complied well and cooperated with the follow-up.

Exclusion Criteria

• Had participated in other clinical trialists of drugs within 4 weeks before the start of the study;

  • Those who had hypertension that was inadequately controlled with a single antihypertensive agent (systolic blood pressure > 140 mmHg and diastolic blood pressure > 90 mmHg, as judged by the investigator), had myocardial ischemia or myocardial infarction of grade I or higher, arrhythmia of grade I and higher (including QT interval ≥ 440 MS), or cardiac dysfunction;

    • Those with a history of substance abuse who are unable to abstain or who have a history of mental disorders;

      • Presence of fungal, bacterial, viral, or other infections that are not controllable or require antibiotic therapy;

        • For subjects with prior chemotherapy use, ≥ grade 2 hematologic toxicity, or ≥ grade 3 nonhematologic toxicity according to nci-ctcae 5.0 criteria at enrollment; ⑥ Known presence of a history of HIV, or hepatitis B (HBsAg positive) or hepatitis C virus (anti HCV positive) nucleic acid test positive;

          • Presence of any indwelling catheter or drain (eg, biliary drain or pleural / peritoneal / pericardial catheter). Use of a dedicated central venous catheter was permitted (colostomy for patients with bowel cancer, percutaneous nephrostomy tube, indwelling Frey catheter, considered by the investigator for implications); ⑧ Presence of brain metastases, presence of a history or disease of the CNS such as seizure disorders, cerebral ischemia / hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the CNS;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CIK combined targeted therapy group	CIK combined targeted therapy group	Combination of CIK cells and targeted therapy
CIK combined with chemotherapy group	CIK combined with chemotherapy group	Combination of CIK cells and chemotherapy
CIK in combination with other therapies	CIK in combination with other therapies	CIK in combination with any two or three of these (i.e., chemotherapy, immunotherapy, and targeted therapy) treatments
CIK combined immunotherapy group	CIK combined immunotherapy group	Combination of CIK cells and immunotherapy

Primary Outcome Measures

Name	Time	Method
Disease control rate (DCR)	up to 5 years	Disease control rate of colorectal cancer
objective response rate (ORR)	up to 5 years	objective response rate of colorectal cancer

Trial Locations

Locations (1)

Southwest Hospital, Army Medical University (Third Military Medical University); 🇨🇳 Chongqing, Chongqing, China